STRS Ohio’s Theriva Biologics TOVX Stock Holding History

STRS Ohio’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1	Closed	-$14K	–	1993
2016 Q3	$14K	Sell	1 -2	-67%	-$29.9K	﹤0.01%	1855
2016 Q2	$45K	Buy	+3	New	+$56.5K	﹤0.01%	1784

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

STRS Ohio's TOVX Position: Q4 2016 in Review

STRS Ohio sold out of Theriva Biologics (TOVX) in Q4 2016, closing a stake of 1 share — an estimated $14K sold.

STRS Ohio first reported a position in TOVX in Q2 2016 and held it in 2 quarters. The position peaked at $45K in Q2 2016. 70 funds tracked by Wall St. Rank hold TOVX as of Q4 2016.

STRS Ohio reported no remaining Theriva Biologics position as of Q4 2016 after selling out during the quarter.
STRS Ohio sold 1 Theriva Biologics share in Q4 2016, an estimated $14K.
STRS Ohio first reported a position in Theriva Biologics in Q2 2016 and held it in 2 quarters.
STRS Ohio's Theriva Biologics position peaked at $45K in Q2 2016.
70 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2016.

Based on STRS Ohio's 13F filing for Q4 2016, filed 24 Jan 2017.